嵌合抗原受体T细胞治疗T淋巴细胞肿瘤靶点及制备工艺的探索  

Target and Manufacturing of Chimeric Antigen Receptor T cells for T-cell Malignancies——Review

作　　者：袁磊[1] 王晶[1] 克晓燕[1] YUAN Lei;WANG Jing;KE Xiao-Yan(Department of Hematology,Peking University Third Hospital,Beijing 100191,China)

机构地区：[1]北京大学第三医院血液病科,北京100191

出　　处：《中国实验血液学杂志》2021年第1期288-292,共5页Journal of Experimental Hematology

摘　　要：T淋巴细胞肿瘤是一组高度异质性的血液系统恶性肿瘤,复发和耐药通常是导致治疗失败的主要原因。既往治疗主要采用放化疗,尽管获得较高的治愈率,但仍有相当比例的患者最终治疗失败。随着单克隆抗体、免疫治疗和细胞治疗进入临床实践,恶性血液病的治愈率得到了显著提高。尤其是嵌合抗原受体T细胞(CAR-T)进入临床,其针对B细胞淋巴瘤和急性B淋巴细胞白血病的疗效已经超越既往任何治疗策略。但是,该治疗方法对T淋巴细胞肿瘤的治疗仍是难题,相关的研究和临床试验均显著落后于B淋巴细胞肿瘤。本文就CAR-T细胞在治疗T淋巴细胞肿瘤中的发展进程,及正在进行的临床试验和已经证实的主要潜在不良反应作一综述。T lymphoid malignancy is a group of highly heterogeneous hematological tumors.Disease recurrence and resistance to therapy are the common causes of failed treatment.Traditional therapy is radiotherapy and chemotherapy,although it has achieved great success.However,many patients still failed to survive following the treatment.With the introduction of monoclonal antibodies,immunotherapy and cellular therapy into clinical practice,the outcome of hematologic malignancies has been significantly improved.In particular,chimeric antigen receptor T cells(CAR-T)showed high efficacy in treating B-cell lymphoma and acute B lymphocytic leukemia and surpassed any previous therapeutic strategies.However,this treatment seldom succeeded in treating T cell malignancies.In this review,the history of CAR-T cells treating T cell malignancies,and the clinical trials,adverse events of previously reported were summarized briefly.

关 键 词：嵌合抗原受体T细胞 T淋巴细胞肿瘤 T细胞淋巴瘤 T淋巴细胞白血病 

分 类 号：R733[医药卫生—肿瘤]